What DraftKings (DKNG)'s Costly Predictions Pivot Means For Shareholders

DraftKings

DraftKings

DKNG

0.00

  • In recent months, DraftKings has shifted significant resources into its new Predictions platform, accepting higher costs and thinner margins while acknowledging limited near-term revenue visibility and regulatory uncertainty around event contracts.
  • This pivot highlights a tension between DraftKings’ push to build a “Super App” around sports, culture, and politics prediction markets and investors’ concerns about whether the company can sustain profitability amid rising competition and state tax pressures.
  • Now we’ll examine how this heavy upfront Predictions spending, with revenue pushed beyond 2026, could reshape DraftKings’ broader investment narrative.

We've uncovered the 11 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

DraftKings Investment Narrative Recap

To own DraftKings today, you need to believe it can turn its early lead in online betting and its new Predictions platform into a durable, profitable ecosystem despite tougher taxes, rising competition, and mounting regulatory scrutiny. The latest selloff on Predictions spending directly affects the key near term catalyst, which is sustaining recent profitability, and sharpens the biggest risk right now that heavier upfront costs and legal uncertainty around prediction markets could offset recent efficiency gains.

The most relevant recent announcement is DraftKings’ launch of its unified Sports & Casino Super App in early March 2026, which folds Sportsbook, Predictions, Casino, and Lottery into a single wallet and experience. This move sits at the center of the Predictions push, because any success in boosting cross sell and engagement through one app could help absorb higher launch costs and state tax pressures, while any stumble would make the margin impact of Predictions spending harder for shareholders to overlook.

Yet even with the Super App rollout, growing legal and social pushback on prediction markets and microbetting is a risk investors should be aware of, because...

DraftKings’ narrative projects $8.9 billion revenue and $904.2 million earnings by 2029.

Uncover how DraftKings' forecasts yield a $35.95 fair value, a 62% upside to its current price.

Exploring Other Perspectives

DKNG 1-Year Stock Price Chart
DKNG 1-Year Stock Price Chart

Some of the lowest ranked analysts were already cautious, assuming DraftKings would reach about US$8.8 billion in revenue and US$1.1 billion in earnings by 2028, and the latest Predictions spending and regulatory headlines could reinforce that more pessimistic view or prompt revisions as you compare it with the more optimistic focus on tech efficiencies and new products.

Explore 6 other fair value estimates on DraftKings - why the stock might be worth over 4x more than the current price!

Reach Your Own Conclusion

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

  • A great starting point for your DraftKings research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.
  • Our free DraftKings research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate DraftKings' overall financial health at a glance.

Ready For A Different Approach?

Our top stock finds are flying under the radar-for now. Get in early:

  • Capitalize on the AI infrastructure supercycle with our selection of the 36 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
  • The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 21 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
  • AI is about to change healthcare. These 31 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.